SCHEMBL124776

SCHEMBL124776

CC(C)(C)N(C(=O)O)[C@@H]1CCCNC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 2/20 0.43
SLC6A11 P48066 1/20 0.43
TSHR P16473 1/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SLC6A13 Q9NSD5 1/20 0.43
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
CYP2D6 P10635 1/20 0.38
CPN1 P15169 2/20 0.35
CPB2 Q96IY4 2/20 0.35
SLC6A2 P23975 8/20 0.33
SLC6A4 P31645 8/20 0.33
KCNH2 Q12809 4/20 0.33
RPLP1 P05386 2/20 0.33
RPLP0 P05388 2/20 0.33
RPS17 P08708 2/20 0.33
RPSA P08865 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14632099 1.00 SLC6A1 (0.43) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL13719286 1.00 SLC6A1 (0.43) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL612826 1.00 SLC6A1 (0.43) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL16763685 0.95 SLC6A1 (0.38) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL1564564 0.95 SLC6A1 (0.38) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL16763687 0.95 SLC6A1 (0.38) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL1290220 0.89 SLC6A4 (0.37) SLC6A1SLC6A11SLC6A13SLC6A2SLC6A4
SCHEMBL476847 0.89 SLC6A4 (0.37) SLC6A1SLC6A11SLC6A13SLC6A2SLC6A4
SCHEMBL743575 0.89 SLC6A4 (0.37) SLC6A1SLC6A11SLC6A13SLC6A2SLC6A4
SCHEMBL28715568 0.85 KDM4E (0.44) SLC6A1SLC6A11TSHRLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-27 US claimed
EP-4655287-A2 INHIBITORS OF NLRP3 MWYNGIL THERAPEUTICS, INC. (US) 2025-12-03 EP disclosed
US-20250302842-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS Jubilant Epipad LLC 2025-10-02 US disclosed
US-12357639-B2 Heterocyclic compounds as pad inhibitors Jubilant Epipad LLC (US) 2025-07-15 US disclosed
US-20250002470-A1 NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ZHEJIANG AIXPLORER BIOTECH CO., LTD. (CN) 2025-01-02 US disclosed
EP-4421068-A1 NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Zhejiang Aixplorer Biotech Co., Ltd. (CN) 2024-08-28 EP disclosed
WO-2024158941-A2 INHIBITORS OF NLRP3 MWYNGIL THERAPEUTICS, INC. (US) 2024-08-02 WO disclosed
CN-118234711-A Cyclopyridazine compounds 尼科治疗有限公司 2024-06-21 CN disclosed
CN-115246817-B Crystal form beta of compound A benzoate, preparation method thereof and pharmaceutical composition containing crystal form beta 深圳信立泰药业股份有限公司 2024-06-18 CN disclosed
US-20240156831-A1 HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS Jubilant Epipad LLC 2024-05-16 US disclosed
US-20110275611-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2011-11-10 US disclosed
EP-2368876-A1 Derivatives of aminoindanes, their preparation and their application in therapeutics SANOFI (FR) 2011-09-28 EP disclosed
WO-2011107474-A1 DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS SANOFI-AVENTIS (FR) 2011-09-09 WO disclosed
US-8012980-B2 Isoquinolinone derivatives ASTRAZENECA AB (SE) 2011-09-06 US disclosed
US-7928107-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-19 US disclosed
US-20110034433-A1 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-02-10 US disclosed
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-27 US disclosed
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-06 US disclosed
EP-2269986-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR Sumitomo Chemical Company, Limited (JP) 2011-01-05 EP disclosed
US-20060173018-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302842-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS NES, VHL, ETV6 SLC6A1 4108/4885SLC6A11 3121/4885TSHR 251/4885
US-20240156831-A1 HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS PADI4, PADI2, PADI1 SLC6A1 3743/4885SLC6A11 3191/4885TSHR 2182/4885
US-20110275611-A1 CHEMICAL COMPOUNDS PDK1, PDK2, PDK3 SLC6A1 4116/4885SLC6A11 4367/4885TSHR 2240/4885
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 SLC6A1 1353/4885SLC6A11 1441/4885TSHR 340/4885
US-20250002470-A1 NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF NOD1, NLRP3, NLRP1 SLC6A1 319/4885SLC6A11 60/4885TSHR 4862/4885
US-20060173018-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 SLC6A1 174/4885SLC6A11 206/4885TSHR 3828/4885
US-12357639-B2 Heterocyclic compounds as pad inhibitors PADI4, PADI2, PADI1 SLC6A1 3743/4885SLC6A11 3191/4885TSHR 2182/4885
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR PDCD2L, NOTUM, OXA1L SLC6A1 1608/4885SLC6A11 191/4885TSHR 3753/4885
US-20110034433-A1 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE TNNI3, TNNT2, PC SLC6A1 3185/4885SLC6A11 4114/4885TSHR 3632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.